In silico screening of indinavir-based compounds targeting proteolytic activity in hiv pr: Binding pocket fit approach

Medicinal Chemistry Research

Volumn 21, Issue 12, 2012, Pages 4060-4068

  Selvaraj, Chandrabose ^a   Singh, Sanjeev Kumar ^a   Tripathi, Sunil Kumar ^a   Reddy, Karnati Konda ^a   Rama, Murugappan ^a  

^a ALAGAPPA UNIVERSITY   (India)

Author keywords

Binding energy; CSD; HIV; Indinavir; Induced fit docking; Interaction energy; Protease

Indexed keywords

COPTOQ; EBEFOG; EBEVAQJON; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; THYPTR10; UNCLASSIFIED DRUG; VAQJON; XICRAC;

ARTICLE; COMPARATIVE STUDY; COMPUTER MODEL; CONFORMATIONAL TRANSITION; DRUG ABSORPTION; DRUG DATABASE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INTOXICATION; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME DEGRADATION; HUMAN IMMUNODEFICIENCY VIRUS; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; ORAL ABSORPTION; PHARMACOKINETIC PARAMETERS; PROTEINASE INHIBITION; SOLVATION;

EID: 84155191319     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9941-5     Document Type: Article

References (34)

1. Adachi M, Ohhara T, Kurihara K, Tamada T, Honjo E, Okazaki N, Arai S, Shoyama Y, Kimura K, Matsumura H, Sugiyama S, Adachi H, Takano K, Mori Y, Hidaka K, Kimura T, Hayashi Y, Kiso Y, Kuroki R (2009) Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography. Proc Natl Acad Sci USA 106:4641–4646
2. Alfonso Y, Monzote L (2011) HIV protease inhibitors: effect on the opportunistic protozoan parasites. Open Med Chem J 5:40–50
3. Allen FH (2002) The Cambridge structural database: a quarter of a million crystal structures and rising. Acta Crystallogr B 58:380– 388
4. Aslani AA, Mangematin V (2009) The future of drug discovery and development: shifting emphasis towards personalized medicine. Technol Forecast Soc Chang 77:203–217
5. Battle GM, Ferrence GM, Allen FH (2010) Applications of the Cambridge structural database in chemical education. J Appl Crystallogr 43:1208–1223
6. Bissantz C, Kuhn B, Stahl M (2010) A medicinal chemist’s guide to molecular interactions. J Med Chem 53:5061–5084
7. Boyd M (2007) Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role? Expert Opin Pharmacother 8:957–964
8. Bruno IJ, Cole JC, Edgington PR, Kessler M, Macrae CF, McCabe P, Pearson J, Taylor R (2002) New software for searching the Cambridge structural database and visualizing crystal structures. Acta Crystallogr B 58:389–397
9. Chen IJ, Foloppe N (2010) Drug-like bioactive structures and conformational coverage with the LigPrep/ConfGen suite: comparison to programs MOE and catalyst. J Chem Inf Model 50:822–839
10. Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW (2003) A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 36:1585–1592
11. Das D, Koh Y, Tojo Y, Ghosh AK, Mitsuya H (2009) Prediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water model. J Chem Inf Model 49:2851–2862
12. Gayathri P, Pande V, Sivakumar R, Gupta SP (2001) A quantitative structure-activity relationship study on some HIV-1 protease inhibitors using molecular connectivity index. Bioorg Med Chem 9:3059–3063
13. Jelsch C, Teeter MM, Lamzin V, Pichon-Pesme V, Blessing RH, Lecomte C (2000) Accurate protein crystallography at ultra-high resolution: valence electron distribution in crambin. Proc Natl Acad Sci USA 97:3171–3176
14. Jiang JK, Ghoreschi K, Deflorian F, Chen Z, Perreira M, Pesu M, Smith J, Nguyen DT, Liu EH, Leister W, Costanzi S, O’Shea JJ, Thomas CJ (2008) Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem 51:8012–8018
15. Jorgensen WL, Duffy EM (2002) Prediction of drug solubility from structure. Adv Drug Deliv Rev 54:355–366
16. Khedkar VM, Ambre PK, Verma J, Shaikh MS, Pissurlenkar RR, Coutinho EC (2010) Molecular docking and 3D-QSAR studies of HIV-1 protease inhibitors. J Mol Model 16:1251–1268
17. Klebe G, Krämer O, Sotriffer C (2004) Strategies for the design of inhibitors of aldose reductase, an enzyme showing pronounced induced-fit adaptations. Cell Mol Life Sci 61:783–793
18. Kurup A, Mekapati SB, Garg R, Hansch C (2003) HIV-1 protease inhibitors: a comparative QSAR analysis. Curr Med Chem 10:1679–1688
19. Loizidou EZ, Zeinalipour-Yazdi CD, Christofides T, Kostrikis LG (2009) Analysis of binding parameters of HIV-1 integrase inhibitors: correlates of drug inhibition and resistance. Bioorg Med Chem 17:4806–4818
20. Lyne PD, Lamb ML, Saeh JC (2006) Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. J Med Chem 49:4805–4808
21. Menendez-Arias L (2002) Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol Sci 23:381– 388
22. Miller JF, Brieger M, Furfine ES, Hazen RJ, Kaldor I, Reynolds D, Sherrill RG, Spaltenstein A (2005) Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles. Bioorg Med Chem Lett 15:3496–3500
23. Mobley DL, Dill KA (2009) Binding of small-molecule ligands to proteins: ‘‘what you see’’ is not always ‘‘what you get’’. Structure 17:489–498
24. Mouchlis VD, Mavromoustakos TM, Kokotos G (2010) Molecular docking and 3D-QSAR CoMFA studies on indole inhibitors of GIIA secreted phospholipase A(2). J Chem Inf Model 50:1589– 1601
25. Perryman AL, Zhang Q, Soutter HH, Rosenfeld R, McRee DE, Olson AJ, Elder JE, Stout CD (2010) Fragment-based screen against HIV protease. Chem Biol Drug Des 75:257–268
26. Provost P, Barat C, Plante I, Tremblay MJ (2006) HIV-l and the micro RNA-guided silencing pathway: an intricate and multifaceted encounter. Virus Res 121:107–115
27. Reddy KK, Singh SK, Dessalew N, Tripathi SK, Selvaraj C (2011) Pharmacophore modelling and atom-based 3D-QSAR studies on N-methyl pyrimidones as HIV-1 integrase inhibitors. J Enzyme Inhib Med Chem. doi:10.3109/14756366.2011.590803
28. Richman DD (2011) Introduction: challenges to finding a cure for HIV infection. Curr Opin HIV AIDS 6:1–3
29. Sengupta D, Verma D, Naik PK (2007) Docking mode of delvardine and its analogues into the p66 domain of HIV-1 reverse transcriptase: screening using molecular mechanics-generalized born/surface area and absorption, distribution, metabolism and excretion properties. J Biosci 32:1307–1316
30. Wang H, Aslanian R, Madison VS (2008) Induced-fit docking of mometasone furoate and further evidence for glucocorticoid receptor 17alpha pocket flexibility. J Mol Graph Model 27:512– 521
31. Waszkowycz B, Clark DE, Gancia E (2011) Outstanding challenges in protein–ligand docking and structure-based virtual screening. Wiley Interdiscip Rev 1:229–259
32. Wu X, Ohrngren P, Ekegren JK, Unge J, Unge T, Wallberg H, Samuelsson B, Hallberg A, Larhed M (2008) Two-carbon-elongated HIV-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic. J Med Chem 51:1053–1057
33. Wu G, Vashishtha SC, Erve JC (2010) Characterization of glutathione conjugates of duloxetine by mass spectrometry and evaluation of in silico approaches to rationalize the site of conjugation for thiophene containing drugs. Chem Res Toxicol 16(8):1393–1404
34. Zavodszky MI, Kuhn LA (2005) Side-chain flexibility in protein-ligand binding: the minimal rotation hypothesis. Protein Sci 14:1104–1114